040IC - Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

Saturday, April 29, 2023

1:30 PM – 3:30 PM CST

Location: S104

Instructional Course Director(s)

Kamal Pohar, MD (he/him/his)

The Ohio State University

Instructional Course Faculty(s)

Ashish Kamat

Professor of Urology
MD Anderson Cancer Center
Cheryl Lee, MD

Professor of Urology
The Ohio State University
JW

J. Witjes, MD

Radboud University Medical Center

Course Description: This course will focus on specific topics discussed in the recent AUA Practice Guidelines for non-muscle invasive bladder cancer (NMIBC) and detail strategies to manage common clinical predicaments involved in the management of these tumors. The course will include short didactic lectures by each of the faculty but will focus predominantly on case presentations highlighting common and often perplexing topics in NMIBC. Specifically, we will focus on (1) important aspects of transurethral resection of bladder tumor, (2) risk stratification for tumor recurrence and progression, and use of cystectomy, (3) selection of the optimal intravesical agent at the right schedule, (4) current definitions of bacillus Calmette-Guérin (BCG) refractory/unresponsive/relapsing disease and (5) drug and surgery options for BCG unresponsive disease. Practical solutions will be presented that can be readily integrated into the office setting. Emphasis is placed on the evaluation of real clinical cases with open audience participation.

Learning Objectives:

Implement current practice guidelines and explain methods and resources to improve transurethral resection of bladder tumor skills.
Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage.
Identify methods to treat significant toxicities from various intravesical therapies.
Define high-risk scenarios that necessitate cystectomy and options for BCG unresponsive disease.
Identify the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and explain current clinical trial designs.